AlphaCentric Advisors »

Design Therapeutics shares owned by AlphaCentric Advisors

Quarter-by-quarter ownership of Design Therapeutics (DSGN) shares owned by AlphaCentric Advisors from 13F filings

Historical chart of AlphaCentric Advisors investment in Design Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Design Therapeutics held by AlphaCentric Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Design Therapeutics by AlphaCentric Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $190k 20k 9.38

More positions owned by AlphaCentric Advisors

Gilead Sciences (GILD)
Invitation Homes (INVH)
Ishares Tr Mbs Etf (MBB)
Euronet Worldwide (EEFT)
Vertex Pharmaceuticals Incorporated (VRTX)
Astrazeneca Sponsored Adr
Alpine Income Ppty Tr (PINE)
Invesco Exchange Traded Fd T S&p500 Pur Val (RPV)
Ishares Tr Rus 1000 Val Etf (IWD)
Ionis Pharmaceuticals (IONS)
Stereotaxis Com New (STXS)
Incyte Corporation (INCY)
Insmed Com Par $.01 (INSM)
AMREP Corporation (AXR)
Argenx Se Sponsored Adr (ARGX)

View all positions for AlphaCentric Advisors

Top funds holding Design Therapeutics

Sr One Capital Management
Point72 Asset Management
Logos Global Management
BlackRock
Baker Bros. Advisors
Vanguard Group
Vivo Capital
Almitas Capital
Driehaus Capital Management
Woodline Partners
Kynam Capital Management
FMR
Geode Capital Management
State Street Corporation
Acadian Asset Management

View all funds holding Design Therapeutics